Liarozole

N/A

Report date: 2022/06/28 10:09:50
NME

Base Information

Drug NameLiarozole
Drug Alias Name利阿唑LiazalR-75251
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytochrome P450 inhibitorsAromatase inhibitorsRetinoic acid receptors modulators
TargetsCytochrome P450AromataseRetinoic acid receptors
Therapy Area/IndicationsPsoriasisIchthyosis, LamellarUrinary Bladder Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesStiefel LaboratoriesJohnson & Johnson Innovative Medicine
Active IndicationsN/A
Inactive IndicationsPsoriasisIchthyosis, LamellarUrinary Bladder Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A